Boston Scientific Corporation
BSX
$102.86
-$0.43-0.42%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.16% | 12.08% | -6.94% | 20.37% | 57.64% |
| Total Depreciation and Amortization | 6.91% | 11.18% | 2.00% | 4.36% | 6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.70% | 11.22% | -12.86% | 271.15% | -5.26% |
| Change in Net Operating Assets | 8.75% | 668.42% | 194.32% | -1,392.86% | -42.07% |
| Cash from Operations | 229.88% | 52.14% | 43.55% | 23.56% | -13.68% |
| Capital Expenditure | -4.47% | -3.75% | 5.79% | -8.39% | -61.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -408.51% | -331.02% | -- | 92.53% | 87.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.42% | -257.14% | -1,412.50% | -25.93% | -5,800.00% |
| Cash from Investing | -75.44% | -251.76% | -624.37% | 67.74% | 41.12% |
| Total Debt Issued | -27.37% | -- | 159.46% | -100.00% | -- |
| Total Debt Repaid | -147.83% | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 43.75% | 64.71% | 28.00% | -3.70% | 26.98% |
| Repurchase of Common Stock | -- | -55.36% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.57% | 55.56% | -516.67% | 71.43% | -7.63% |
| Cash from Financing | -85.15% | 1,326.67% | -56.25% | -44.19% | 2,373.91% |
| Foreign Exchange rate Adjustments | 657.14% | -325.00% | 220.00% | 66.67% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -78.28% | -2,554.55% | -180.31% | 495.10% | 496.97% |